scholarly journals Metastatic plasmacytoid bladder cancer causing malignant priapism

2019 ◽  
Vol 12 (7) ◽  
pp. e228088
Author(s):  
Ryan Pereira ◽  
Marlon Perera ◽  
Handoo Rhee
Keyword(s):  
Bladder Cancer ◽  
Anterior Abdominal Wall ◽  
Subcutaneous Tissue ◽  
Bladder Wall ◽  
Transitional Cell ◽  
Penile Shaft ◽  
Iliac Region ◽  
Left Flank ◽  
Bladder Disease ◽  
Malignant Priapism

An 81-year-old man presented to medical services with pelvic pain and evolving urinary retention over 3 months. The patient was found to have a tense glans and penile shaft with surrounding induration consistent with malignant priapism. The extent of the induration included the suprapubic region, scrotum, left iliac region and left flank. A CT scan demonstrated an enhancing, pedunculated lesion arising from the anterior bladder wall measuring 30×31×20 mm. There were multiple enlarged left inguinal lymph nodes. Core biopsies of the subcutaneous tissue on the anterior abdominal wall demonstrated plasmacytoid urothelial carcinoma. The majority of patients with plasmacytoid variant of transitional cell carcinoma will present with >stage 3 bladder disease

scholarly journals Dynamic magnetic-resonance cystography in diagnosis of perivesical fat invasion in bladder cancer

2020 ◽  
Vol 15 (4) ◽  
pp. 93-99
Author(s):  
E. G. Grigoriev ◽  
I. G. Frolova ◽  
E. A. Usynin ◽  
N. V. Vasiliev ◽  
A. V. Usova ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Magnetic Resonance ◽  
Bladder Wall ◽  
Transitional Cell ◽  
Intensity Change ◽  
Imaging Method ◽  
Magnetic Resonance Signal ◽  
Resonance Signal ◽  
Verification Method ◽  
Dynamic Magnetic Resonance

Objective: to evaluate the diagnostic capabilities of the dynamic magnetic-resonance cystography technique in detecting invasion of perivesical fat in case of bladder cancer.Materials and methods. The study included 125 patients (105 male and 20 females, mean 62.6 Ѓ} 11.0 years) with transitional cell carcinoma of the bladder. To assess the accuracy of the dynamic cystography method, cases with a tumor size of more than 20 mm, affecting the wall outside the bladder triangle, were selected with suspicion of perivesical fat invasion on magnetic-resonance scans. A furacilin solution was fractional injected into the catheterized bladder to obtain repeated series of T2‑haste-FS images until the bladder was completely expanded.Results. In postprocessing, the selection of areas of interest (ROI) was performed along the contour of the affected wall in the cross section through the center of the tumor. Comparison of the displacement of the affected and intact walls by a diagram of the values of the intensity of the magnetic-resonance signal in the dynamics of bladder dilatation was evaluated. The verification method was the morphological study of the surgical material after the operative treatment. The limit of values with a more likely lesion of perivesical fat was found, which is less than 11 % of the intensity change of the magnetic-resonance signal in selected ROIs during bladder wall expansion.Conclusion. The effectiveness of dynamic magnetic-resonance cystography in the differential diagnosis of perivesical fat infiltration in bladder cancer is characterized by a sensitivity of 90.0 %, a specificity of 93.3 %, and an accuracy of 92.0 %. The proposed technique improves the accuracy of the magnetic resonance imaging method with suspected infiltration of perivesical fat and is well tolerated by patients.

Superficial bladder cancer: the primacy of grade in the development of invasive disease.

1987 ◽  
Vol 5 (1) ◽  
pp. 125-130 ◽  
Author(s):  
F M Torti ◽  
B L Lum ◽  
D Aston ◽  
N MacKenzie ◽  
M Faysel ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Logistic Regression ◽  
Superficial Bladder Cancer ◽  
Medical Center ◽  
Bladder Wall ◽  
Transitional Cell ◽  
Invasive Disease ◽  
Deep Muscle ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasion

Tumor characteristics thought to predict for development of deep muscle invasion after resection of superficial bladder cancer were retrospectively analyzed in 252 patients with transitional cell carcinoma of the bladder at Stanford University Medical Center. Stage 0 patients accounted for 190 of the patient population (75.5%), while stage A and B1 comprised 51 (20%) and 11 (4.5%), respectively. The median follow-up time was 62 months. Forty-three patients subsequently developed deep muscle invasion; these included 24 (12.6%), 14 (27.5%), and 5 (45.5%) of stage 0, A, and B1 patients (P = .002), or 15 (10%), 15 (9%), and 13 (33%) of grade 1, 2, and 3 tumors (P = .001), respectively. When analyzed by univariate logistic regression, grade (P = .0001) and stage (P = .0118) were significant predictors for invasive disease. Site of tumor and number of tumors at presentation were not significant factors for invasion deep into the bladder wall. When multiple logistic regression was performed, only grade remained as a significant tumor variable to predict for invasive disease (P less than .0091). Risk of invasive disease did not appear to increase with increasing number of recurrences, remaining at approximately an 11% invasion rate through 12 recurrences. In this analysis, grade was the most significant tumor variable in superficial bladder cancer predicting for the development of invasive carcinoma. Future clinical trials for definitive or adjuvant therapy of this disease must stratify for this variable.

405: Previous History of Bladder Cancer is an Independent Prognostic Factor for Upper Tract Transitional Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 135-135
Author(s):  
Eiji Kikuchi ◽  
Akira Miyajima ◽  
Ken Nakagawa ◽  
Mototsugu Oya ◽  
Takashi Ohigashi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Factor ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Previous History ◽  
Independent Prognostic Factor ◽  
Upper Tract ◽  
History Of

CLINICAL SYMPTOMS, ULTRASOUND AND HISTOPATHOLOGY OF TUMORLIKE LESIONS OF THE BLADDER.

2017 ◽  
pp. 41-46
Author(s):  
Van Mao Nguyen ◽  
Thi Bich Chi Nguyen
Keyword(s):  
Bladder Cancer ◽  
Bladder Tumor ◽  
Clinical Symptoms ◽  
Bladder Wall ◽  
Lower Abdominal Pain ◽  
University Hospital ◽  
Wall Thickening ◽  
Health Examination ◽  
Ultrasound Images ◽  
Key Words Bladder Cancer

Background: Bladder cancer is one of the most frequent type of urinary cancer which has been ever increasing. For the better treatment, the early discovery and definite diagnosis of this disease played an important role. Objective: To describe some clinical symptoms and ultrasound features of tumorlike lesions of the bladder. To diagnose and classify the histopathology of tumorlike lesions of the bladder. Materials, method: cross - sectional study on 64 cases in Hue University Hospital and Hue central hospital from April, 2016 to February, 2017. Results: Hematuria was the most common reason that patients went to hospital (79.7%). Lower abdominal pain and irritation during urination accounting for 9.4% and 6.2% respectively. Only 3 patients with bladder cancer were accidentally discovered through periodic health examination (4.7%). The characteristics of hematuria in bladder tumor was flesh red urine (62.5%) and total hematuria (60.7%). With ultrasonography, the results of 64 patients were divided in 3 groups as follow: bladder tumor, which was the highest rate 87.5%, bladder polyp was 3.1% and focal bladder wall thickening was 9.4%. Of which, the vast majority of these ultrasound images was tumor - like lesions protruding in the lumen of the bladder (75%), the rest was wall thickening lesions (25%). Tumors were different in size, the biggest tumor was 7cm in diameter and the smallest was 0.6cm. Those with the diameter 3cm or bigger accounting for 42.2%, the smaller was 57.8%. Most cases have only one lesion (62.5%) and at lateral wall (46.6%). Histopathologically, cancer was 59/64 case (92.2%): urothelial carcinoma was 98.3 %, squamous cell carcinomawas 1.7% and 5 cases (7.8%) were benign. Most cancerous cases were poorly differentiated, grade II (50.9%) and grade III (32.2%). The stage T1NxMx was 20.3% and worse than T2MxNx was 79.7%. Conclusion: hematuria was the most popular symptom, suggesting bladder cancer. Clinical diagnosing bladder cancer was not high sensitive (61.01%). Ultrasound could detect bladder tumor with high sensitive (89.8%). These patients also needed histopathology classification to diagnose and finally choose the best method for the appropriate treatment. Key words: bladder cancer, histopathology, ultrasound, uroepithelial carcinoma, hematuria

Surface Labeling with Adhesion Protein FimH Improves Binding of Immunotherapeutic Agent Salmonella Ty21a to the Bladder Epithelium

2020 ◽  
pp. 1-12
Author(s):  
Maroeska J. Burggraaf ◽  
Lisette Waanders ◽  
Mariska Verlaan ◽  
Janneke Maaskant ◽  
Diane Houben ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Antitumor Activity ◽  
Bladder Wall ◽  
Bladder Epithelium ◽  
Modest Improvement ◽  
Adhesion Protein ◽  
Survival Experiment ◽  
Muscle Invasive

BACKGROUND: Bladder cancer is the ninth most common cancer in men. 70% of these tumors are classified as non-muscle invasive bladder cancer and those patients receive 6 intravesical instillations with Mycobacterium bovis BCG after transurethral resection. However, 30% of patients show recurrences after treatment and experience severe side effects that often lead to therapy discontinuation. Recently, another vaccine strain, Salmonella enterica typhi Ty21a, demonstrated promising antitumor activity in vivo. Here we focus on increasing bacterial retention in the bladder in order to reduce the number of instillations required and improve antitumor activity. OBJECTIVE: To increase the binding of Ty21a to the bladder wall by surface labeling of the bacteria with adhesion protein FimH and to study its effect in a bladder cancer mouse model. METHODS: Binding of Ty21a with surface-labeled FimH to the bladder wall was analyzed in vitro and in vivo. The antitumor effect of a single instillation of Ty21a+FimH in treatment was determined in a survival experiment. RESULTS: FimH-labeled Ty21a showed significant (p <  0.0001) improved binding to mouse and human cell lines in vitro. Furthermore, FimH labeled bacteria showed ∼5x more binding to the bladder than controls in vivo. Enhanced binding to the bladder via FimH labeling induced a modest improvement in median but not in overall mice survival. CONCLUSIONS: FimH labeling of Ty21a significantly improved binding to bladder tumor cells in vitro and the bladder wall in vivo. The improved binding leads to a modest increase in median survival in a single bladder cancer mouse study.

897 Transitional cell bladder cancer proteomic mapping and risk of progression

2012 ◽  
Vol 11 (1) ◽  
pp. e897-e897a
Author(s):  
I. Galante Romo ◽  
L.A. San José Manso ◽  
J. Casado Varela ◽  
A. López Farré ◽  
J. Blázquez Izquierdo ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Transitional Cell ◽  
Cell Bladder Cancer ◽  
Risk Of Progression ◽  
Transitional Cell Bladder Cancer

scholarly journals Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer

2017 ◽  
Vol 89 (2) ◽  
pp. 102 ◽  
Author(s):  
Ali Serdar Gözen ◽  
Paolo Umari ◽  
Walter Scheitlin ◽  
Fuat Ernis Su ◽  
Yigit Akin ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Recurrent Disease ◽  
Bladder Wall ◽  
Invasive Bladder Cancer ◽  
Outpatient Basis ◽  
High Grade ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Background&amp;Aim: High grade non-muscle invasive bladder cancer (NMIBC) is common in urological practice. Most of these cancers are or become refractory to intravesical immunotherapy and chemotherapy. Here we evaluated the efficacy of combined local bladder hyperthermia and intravesical mitomycin-C (MMC) instillation in patients with high-risk recurrent NMIBC. Materials and methods: Between February 2014 and December 2015, 18 patients with high risk NMIBC were enrolled. Patients were treated in an outpatient basis with 6 weekly induction sessions followed by monthly maintenance sessions with intravesical MMC in local hyperthermia with bladder wall thermo-chemotherapy (BWT) system (PelvixTT system, Elmedical Ltd., Hod Hasharon, Israel). The follow-up regimen included cystoscopy after the induction cycle and thereafter with regular intervals. Time to disease recurrence was defined as time from the first intravesical treatment to endoscopic or histological documentation of a new bladder tumour. Adverse events were recorded according to CTC 4.0 (Common Toxicity Criteria) score system. Results: Mean age was 72 (32-87) years. 10 patients had multifocal disease, 9 had CIS, 6 had recurrent disease and 2 had highly recurrent disease (&gt; 3 recurrences in a 24 months period). 6 patients underwent previous intravesical chemotherapy with MMC. The average number of maintenance sessions per patient was 7.6. After a mean follow-up of 433 days, 15 patients (83.3%) were recurrence-free. 3 patients had tumour recurrence after a mean period of 248 days without progression. Side effects were limited to grade 1 in 2 patients and grade 2 in 1 patient. Conclusions: BWT seems to be feasible and safe in high grade NMIBC. More studies are needed to identify the subgroup of patients who may benefit more from this treatment.

scholarly journals Paraneoplastic production of heparin-like anticoagulant in a patient with metastatic transitional cell carcinoma

2013 ◽  
Vol 3 (5) ◽  
pp. 61 ◽  
Author(s):  
Kelly N. Fahl ◽  
Stephen A. Poon ◽  
Ketan K. Badani ◽  
Mitchell C. Benson
Keyword(s):  
Bladder Cancer ◽  
Breast Carcinoma ◽  
Liver Failure ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Hematological Malignancies ◽  
Transitional Cell ◽  
Carcinoma Breast ◽  
Severe Coagulopathy

It has been reported that patients with bladder cancer have widelyvarying paraneoplastic consequences, including metabolic, dermatologic,myopathic and neurologic disturbances. We report a case of a52-year-old man with advanced transitional cell carcinoma and livermetastases, who developed a severe coagulopathy following roboticradical cystoprostatectomy due to circulating heparin-like substancesprior to onset of liver failure. Heparin-like anticoagulant production isa rare paraneoplastic effect documented in concert with transitionalcell carcinoma, breast carcinoma and hematological malignancies.

Glutathione S–Transferase Null Genotypes in Transitional Cell Bladder Cancer

2000 ◽  
Vol 37 (6) ◽  
pp. 660-664 ◽  
Author(s):  
Ioannis Georgiou ◽  
Ioannis F. Filiadis ◽  
Yannis Alamanos ◽  
Ioanna Bouba ◽  
Xenophon Giannakopoulos ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Transitional Cell ◽  
Cell Bladder Cancer ◽  
Transitional Cell Bladder Cancer

Repeated Intravesical Instillations of an Adenoviral Vector in Patients With Locally Advanced Bladder Cancer: A Phase I Study of p53 Gene Therapy

2003 ◽  
Vol 21 (12) ◽  
pp. 2247-2253 ◽  
Author(s):  
Lance C. Pagliaro ◽  
Afsaneh Keyhani ◽  
Dallas Williams ◽  
Denise Woods ◽  
Baoshun Liu ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Bladder Cancer ◽  
Gene Transfer ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Locally Advanced ◽  
Transitional Cell ◽  
P53 Gene ◽  
Advanced Bladder Cancer ◽  
Intravesical Instillations

Purpose: We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer. Patients and Methods: Patients with measurable, locally advanced transitional-cell carcinoma of the bladder who were not candidates for cystectomy were eligible. On a 28-day cycle, intravesical instillations of INGN 201 (Ad5CMV-p53) were administered on days 1 and 4 at three dose levels (1010 particles to 1012 particles) or on either 4 or 8 consecutive days at a single dose level (1012 particles). Results: Thirteen patients received a total of 22 courses without dose-limiting toxicity. Specific transgene expression was detected by reverse transcriptase polymerase chain reaction in bladder biopsy tissue from two of seven assessable patients. There were no changes in p53, p21waf1/cip1, or bax protein levels in bladder epithelium evident from immunohistochemical analysis of 11 assessable patients. Outpatient administration of multiple courses was feasible and well tolerated. A patient with advanced superficial bladder cancer showed evidence of tumor response. Conclusion: Intravesical instillation of Ad5CMV-p53 is safe, feasible, and biologically active when administered in multiple doses to patients with bladder cancer. Observations from this study indicate that this treatment has an antitumor effect in superficial transitional-cell carcinoma. Improvements in the efficiency of gene transfer and the levels of gene expression are required to develop more effective gene therapy for bladder cancer.

Sign in / Sign up

Export Citation Format

Share Document